Sign In
Buy AUPH
$15.67
+0.280 (+1.82%)
At Close: Jun 03, 2026
Aurinia Adds Two Assets To Expand Its Immunology Pipeline
06:39am, Tuesday, 17'th Aug 2021
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held Thund
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
06:05am, Tuesday, 17'th Aug 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the Company's rare a
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
07:55am, Monday, 09'th Aug 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a firesid
Why Aurinia Pharmaceuticals Stock Was Surging on Friday
01:54pm, Friday, 06'th Aug 2021
Investors were relieved to see significant sales from the company's first commercial-stage drug.
AUPH Stock Price Increases Over 14% Pre-Market: Why It Happened
05:56am, Friday, 06'th Aug 2021
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) increased by over 14% pre-market. This is why it happened.
Aurinia Pharmaceuticals Inc. (AUPH) CEO John Leonard on Q2 2021 Results - Earnings Call Transcript
11:06pm, Thursday, 05'th Aug 2021
Aurinia Pharmaceuticals Inc. (AUPH) CEO John Leonard on Q2 2021 Results - Earnings Call Transcript
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
09:17pm, Thursday, 05'th Aug 2021
Aurinia (AUPH) delivered earnings and revenue surprises of -5.71% and 32.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
06:05am, Monday, 26'th Jul 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2021 financial results o
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
05:30pm, Friday, 16'th Jul 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for sever
New Strong Sell Stocks for July 15th
11:35am, Thursday, 15'th Jul 2021
ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
07:05am, Wednesday, 30'th Jun 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced the recipients of five $50,000 grant awards to support implementation patient navi
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company's licensing partner, Otsuka Pharmace
Aurinia Pharmaceuticals: Recent Sell-Off Provides A Great Entry Point
05:16am, Monday, 21'st Jun 2021
Aurinia Pharmaceuticals: Recent Sell-Off Provides A Great Entry Point
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
06:05am, Monday, 14'th Jun 2021
VICTORIA, British Columbia--(BUSINESS WIRE)---- $AUPH--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D.,
Aurinia Announces Results of the 2021 Annual General Meeting
07:05pm, Monday, 07'th Jun 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of th
